Literature DB >> 33210746

Silent New Brain MRI Lesions in Children with MOG-Antibody Associated Disease.

Giulia Fadda1, Brenda Banwell1,2, Patrick Waters3, Ruth A Marrie4, E Ann Yeh5, Julia O'Mahony6, Douglas A Arnold7, Amit Bar-Or1,2,7.   

Abstract

Anti-myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) antibodies are associated clinically with either a monophasic or relapsing disease course. We investigated the frequency and clinical importance of acquired asymptomatic brain magnetic resonance imaging (MRI) lesions in a prospective incident cohort of 74 MOG-IgG positive children with serial MRI scans over a median of 5 years from presentation. Silent new lesions were detected in 14% of MOG-IgG positive participants, most commonly within the first months post-onset, with a positive predictive value for clinically relapsing disease of only 20%. Detection of asymptomatic lesions alone need not prompt initiation of chronic immunotherapy. ANN NEUROL 2021;89:408-413.
© 2020 American Neurological Association.

Entities:  

Year:  2020        PMID: 33210746     DOI: 10.1002/ana.25957

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  9 in total

Review 1.  Pediatric Acquired Demyelinating Disorders.

Authors:  J Nicholas Brenton
Journal:  Continuum (Minneap Minn)       Date:  2022-08-01

Review 2.  Myelin Oligodendrocyte Glycoprotein-Associated Disorders.

Authors:  Erin Longbrake
Journal:  Continuum (Minneap Minn)       Date:  2022-08-01

Review 3.  Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management.

Authors:  Elia Sechi; Laura Cacciaguerra; John J Chen; Sara Mariotto; Giulia Fadda; Alessandro Dinoto; A Sebastian Lopez-Chiriboga; Sean J Pittock; Eoin P Flanagan
Journal:  Front Neurol       Date:  2022-06-17       Impact factor: 4.086

4.  Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI.

Authors:  Pietro Zara; Valentina Floris; Eoin P Flanagan; A Sebastian Lopez-Chiriboga; Brian G Weinshenker; Paolo Solla; Elia Sechi
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-11-19

5.  Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD.

Authors:  Alessandro Dinoto; Elia Sechi; Sergio Ferrari; Alberto Gajofatto; Riccardo Orlandi; Paolo Solla; Alessandra Maccabeo; Giorgia Teresa Maniscalco; Vincenzo Andreone; Arianna Sartori; Paolo Manganotti; Sarah Rasia; Ruggero Capra; Chiara Rosa Mancinelli; Sara Mariotto
Journal:  Mult Scler Relat Disord       Date:  2021-11-22       Impact factor: 4.339

6.  Radiological Features for Outcomes of MOGAD in Children: A Cohort in Southwest China.

Authors:  Xiao Fan; Qi Li; Tingsong Li; Xiaoyan He; Chuan Feng; Bin Qin; Ye Xu; Ling He
Journal:  Neuropsychiatr Dis Treat       Date:  2022-08-26       Impact factor: 2.989

7.  Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria.

Authors:  Giulia Fadda; Patrick Waters; Mark Woodhall; Robert A Brown; Julia O'Mahony; Denise A Castro; Giulia Longoni; E Ann Yeh; Ruth Ann Marrie; Douglas L Arnold; Brenda Banwell; Amit Bar-Or
Journal:  Mult Scler       Date:  2022-05-17       Impact factor: 5.855

8.  Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.

Authors:  Valentina Camera; Leah Holm-Mercer; Ali Asgar Hatim Ali; Silvia Messina; Timotej Horvat; Wilhelm Kuker; Maria Isabel Leite; Jacqueline Palace
Journal:  JAMA Netw Open       Date:  2021-12-01

9.  Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders.

Authors:  Elia Sechi; Karl N Krecke; Steven A Messina; Marina Buciuc; Sean J Pittock; John J Chen; Brian G Weinshenker; A Sebastian Lopez-Chiriboga; Claudia F Lucchinetti; Nicholas L Zalewski; Jan Mendelt Tillema; Amy Kunchok; Salvatore Monaco; Padraig P Morris; James P Fryer; Adam Nguyen; Tammy Greenwood; Stephanie B Syc-Mazurek; B Mark Keegan; Eoin P Flanagan
Journal:  Neurology       Date:  2021-07-14       Impact factor: 9.910

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.